Ginkgolide B(Synonyms: BN-52021)

上海金畔生物科技有限公司提供天然产物萜类及其苷类Terpenoids and Glycosides。

Ginkgolide B (Synonyms: BN-52021) 纯度: ≥98.0%

Ginkgolide B (BN-52021) 是一种萜类物质,是银杏叶中的重要的活性物质之一。

Ginkgolide B(Synonyms: BN-52021)

Ginkgolide B Chemical Structure

CAS No. : 15291-77-7

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥500 In-stock
10 mg ¥360 In-stock
50 mg ¥1220 In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

Ginkgolide B 相关产品

相关化合物库:

  • Covalent Screening Library Plus
  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Metabolism/Protease Compound Library
  • Natural Product Library
  • Anti-Cancer Compound Library
  • Human Endogenous Metabolite Compound Library
  • Covalent Screening Library
  • Medicine Food Homology Compound Library
  • Terpenoids Library
  • Traditional Chinese Medicine Monomer Library
  • Food-Sourced Compound Library
  • Rare Diseases Drug Library

生物活性

Ginkgolide B (BN-52021), an important active terpenoid from Ginkgo biloba leaves, is reported to increase cell viability and decrease cell apoptosis. IC50 value: Target: In vitro: Ginkgolide B (0.2 or 0.4 μg/ml) was added to the culture medium in vitro led to increases in cell viability and decreases in the number of hippocampal cells undergoing AAPH-induced apoptosis [1]. Ginkgolide B caused a dose-related protection against dysrhythmias; the antiarrhythmic effect of ginkgolide B was comparable to that of diltiazem and superior to the activity of metoprolol. Ginkgolide B can presumably prevent the re-entry mechanism involved in the development of ischemia-induced rhythm disturbances [2]. In vivo: Oral administration of ginkgolide B (2 mg/kg/day, p.o.) caused a significant increase in cell viability and a highly significant decrease in the numbers of both spontaneously occurring and AAPH-induced apoptoses.

IC50 & Target

Human Endogenous Metabolite

 

分子量

424.40

Formula

C20H24O10

CAS 号

15291-77-7

中文名称

银杏内酯 B;白果苦内酯 B

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : ≥ 100 mg/mL (235.63 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.3563 mL 11.7813 mL 23.5627 mL
5 mM 0.4713 mL 2.3563 mL 4.7125 mL
10 mM 0.2356 mL 1.1781 mL 2.3563 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (5.89 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.89 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (5.89 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.89 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (5.89 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.89 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。
参考文献
  • [1]. Jean R. Rapin, et al. In vitro and in vivo effects of an extract of Ginkgo biloba (EGb 761), ginkgolide B, and bilobalide on apoptosis in primary cultures of rat hippocampal neurons. Drug Development Research, 1998, 45 (1):1-43

    [2]. Matyas Koltai, et al. Ginkgolide B protects isolated hearts against arrhythmias induced by ischemia but not reperfusion. European Journal of Pharmacology, 1989, 164 (2): 293-302